logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Journal Article
|Commentary

Universal regimens or universal access to drug susceptibility testing for tuberculosis?

Acquah R, Furin J
Download

Similar Content
Loading...
Loading...
Loading...
Universal regimens or universal access to drug susceptibility testing for tuberculosis? | Journal Article / Commentary | MSF Science Portal
Abstract
A universal regimen. At times this appears to be the Holy Grail in tuberculosis treatment. For decades, policy makers, public health specialists, and donors have argued that in order to control—and these days to “End TB”—a simplified approach that offers everyone the same regimen is our best bet. They argue that countries, programmes, and the people who work in them, are incapable of managing complexity when it comes to tackling tuberculosis. Fears abound that recommending anything other than a basic treatment algorithm will lead to mismanagement and a tuberculosis crisis worse that what we see now. Never mind that such an approach erases patient individuality and unique human treatment needs. “Keep it simple” remains the mantra in tuberculosis control to this day.

Subject Area

tuberculosis

Languages

English
DOI
10.1016/S1473-3099(18)30742-4
Published Date
01 Mar 2019
PubMed ID
30744961
Journal
Lancet Infectious Diseases
Volume | Issue | Pages
Volume 19, Issue 3, Pages 224-225
Issue Date
2019-03-01
Dimensions Badge